LigaChem Biosciences' LCB71 Achieves Complete Remission in All Patients in First-Line Lymphoma Treatment

[Financial News] OliX said on the 28th that LCB71, a ROR1-targeted Antibody-Drug Conjugate (ADC) developed by LigaChem Biosciences and licensed out to a global partner, showed a strong early response rate in a first-line diffuse large B-cell lymphoma (DLBCL) trial. CStone Pharmaceuticals, which is developing LCB71 under the name CS5001, disclosed the clinical data in its semiannual business report. CStone is developing LCB71 as CS5001.
According to the released data, all 31 patients in the 40-90 μg/kg dose range showed an objective response in a trial combining R-CHOP and LCB71 for first-line DLBCL, resulting in a 100% objective response rate (ORR). Notably, the complete remission (CR) rate was also 100% in each dose group.
It is also noteworthy that complete remission was confirmed even at the low dose of 40 μg/kg. Because antitumor effects were seen even at lower doses, the result may provide important evidence for finding the optimal dose and dosing interval that can improve tolerability while preserving efficacy.
LCB71 is a ROR1-targeted ADC jointly developed by OliX and ABL Bio Inc. It incorporates OliX's linker technology, designed to be selectively cleaved in tumor tissue, as well as its in-house PBD prodrug payload.
The latest results are significant because they suggest LCB71 may be effective not only as a second-line treatment for previously treated patients, but also in the early, first-line setting. In particular, ROR1 is known to be expressed in several blood cancers, raising the possibility that its use could expand to a wider range of indications.
However, the latest findings alone are not enough to confirm LCB71's clinical superiority. The currently available data are early results from a limited patient group, so further trials in larger populations will be needed to verify durability of response, safety, and efficacy compared with existing treatments.
Based on the accumulated clinical data, CStone Pharmaceuticals has temporarily paused the trial and moved into a stage of evaluating the balance between efficacy and safety in order to determine the optimal dose and dosing schedule.
With complete remission confirmed even at the lowest dose, the key focus in future development is expected to be finding a dosing strategy that maintains efficacy while minimizing side effects.
A LigaChem Biosciences official said, "A 100% complete remission rate across all dose ranges in first-line DLBCL is an encouraging result that supports the clinical potential of a ROR1 ADC." The official added, "Since sufficient efficacy was confirmed even at low doses, we expect to establish the optimal dose and secure a competitive profile in late-stage trials."

[email protected] Kang Jung-mo Reporter